Biogen and Denali reported Phase 2b LUMA results for BIIB122 (DNL151) in early-stage Parkinson's disease, and the study found the drug did not slow disease progression. The negative clinical readout is a setback for the program and may pressure sentiment around both companies' neuroscience pipelines.
Biogen and Denali reported Phase 2b LUMA results for BIIB122 (DNL151) in early-stage Parkinson's disease, and the study found the drug did not slow disease progression. The negative clinical readout is a setback for the program and may pressure sentiment around both companies' neuroscience pipelines.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately negative
Sentiment Score
-0.35
Ticker Sentiment
